SRC and familial pancreatic carcinoma: To characterize their interaction in the context of pancreatic cancer, S2VP10 and MIA PaCa-2 cells were treated with Src inhibitor (Dasatinib) or/and FAK inhibitor (PF573228), followed by Western blot analysis for Src and FAK activation (Figs. 5A and 5B).